---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-046296"
form_type: "8-K"
ticker: null
cik: "0001426332"
company_name: "NGM BIOPHARMACEUTICALS INC"
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T14:57:17.696039+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NGM Biopharmaceuticals to be acquired by Column Group affiliates for $1.55/share (80% premium), going private

## Summary
- Acquisition price $1.55/share in cash, an 80% premium to Dec 29, 2023 closing price before TCG's expression of interest.
- Total equity value ~$135M on fully diluted basis; NGM had ~$166M cash/securities as of Sep 30, 2023, ~$144.2M as of Dec 31.
- Special Committee of independent directors unanimously recommends deal; TCG (26% holder) and rollover stockholders contribute shares instead of cash.
- Tender offer requires majority of unaffiliated shares tendered; no financing condition; expected close Q2 2024; NGM to become private.

## SEC filing metadata
- accession: 0001193125-24-046296
- form_type: 8-K
- cik: 0001426332
- company_name: NGM BIOPHARMACEUTICALS INC
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/0001193125-24-046296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/d796872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-046296
- JSON: https://secwatch.observer/filing/0001193125-24-046296.json
- Plain text: https://secwatch.observer/filing/0001193125-24-046296.txt

## Key facts
- Material Agreements
  NGM BIOPHARMACEUTICALS INC entered into Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. (effective 2024-02-25).
  - Action: entry
  - Agreement: merger
  - Counterparty: Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc.
  - Effective: 2024-02-25
  source text: On February 25, 2024, NGM Biopharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), and Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/0001193125-24-046296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.